Piper Sandler Maintains Overweight on Sarepta Therapeutics, Maintains $205 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Biren Amin maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $205 price target.

July 01, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Biren Amin maintains an Overweight rating on Sarepta Therapeutics with a $205 price target, indicating confidence in the company's future performance.
The reaffirmation of an Overweight rating and a high price target of $205 by Piper Sandler suggests strong confidence in Sarepta Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100